Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 11, 2000, Pages 9-14

  Chien, K R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CELL SURVIVAL; CONFERENCE PAPER; DISEASE EXACERBATION; GENE LOSS; GENETIC SUSCEPTIBILITY; HEART FAILURE; ONCOGENE NEU; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARDIOMYOPATHY, DILATED; CYTOKINE RECEPTOR GP130; CYTOKINES; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTROPHY; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, ANIMAL; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 0034471831     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Stress pathways and heart failure
2. Molecular biology of cardiac hypertrophy and heart failure
3. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy
4. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways
5. The receptor for ciliary neurotrophic factor
6. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice
7. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival
8. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy
9. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes
10. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress
11. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion
12. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney
13. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2
14. Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms
15. Characterization of the structure and function of a novel MAP kinase kinase (MKK6)
16. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
17. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta)
18. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family
19. Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes
20. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy
21. Molecular advances in cardiovascular biology
22. Signaling pathways for cardiac hypertrophy and failure
23. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy
24. Gq and ras-dependent pathways mediate hypertrophy of neonatal rat ventricular myocytes following alpha1-adrenergic stimulation
25. Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice
26. Enhanced Galphaq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure
27. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-jun NH2-terminal kinase in ventricular muscle cells
28. Apoptosis: Basic mechanisms and implications for cardiovascular disease
29. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
30. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes
31. Cell-cell signaling. neu tack on neuregulin
32. Requirement of ErbB2 for signaling by interleukin-6 in prostate carcinoma cells